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ABSTRACT
A novel and sensitive chemiluminescence (CL) method was developed and validated for the determination of citalopram in bulk
dosage form and in pharmaceutical preparations. The method is based on the use of Cu2+-grafted oxidized multiwall carbon
nanotubes (Cu/ox-MWCNTs). The weak CL signal arising from the reaction of an alkaline luminol-H2O2 system was significantly
enhanced by the addition of citalopram in the presence of ox-MWCNTs/Cu2+. Furthermore, ox-MWCNTs/Cu2+ exhibited excep-
tional catalytic activity towards the oxidation of luminol in the luminol-H2O2 CL reaction. Multiwalled carbon nanotubes
(MWCNTs) were characterized by scanning electron microscopy (SEM), which also showed the attachment of Cu2+ to MWCNTs.
Various factors affecting CL intensity were carefully investigated and optimized for citalopram quantitation. The CL intensity
was proportional to citalopram concentration in the range 0.2–8.0 µg mL–1, with a correlation coefficient of 0.996. The limit of
detection (LOD) and limit of quantification were 2.29 × 10–5 µg mL–1 and 7.64 × 10–5 µg mL–1, respectively, and its reproducibility
was satisfactory with a relative standard deviation (RSD) of 2.59 % (n = 5). The interference effects of common excipients were
studied, and the developed method was effectively applied for the determination of citalopram in pure form and in pharmaceuti-
cal preparations. Percentage recoveries were calculated and ranged from 98.67 to 101.46 % for the pure form and from 97.38 to
101.72 % for pharmaceutical preparations.
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1. Introduction
Citalopram (CIT; 1- (3-dimethylaminopropyl)-1-(4-fluoro-
phenyl)-1, 3-dihydroisobezofuran-5-carbonitrile)1 is a second
generation selective serotonin reuptake inhibitor, which belongs
to the group of drugs known as antidepressants. CIT has
broad-spectrum therapeutic activity against depression, anxiety,
and obsessive and impulse control disorders.2,3 It has also been
reported to reduce the symptoms of diabetic neuropathy and
premature ejaculation 4,5, and may be effective for the treatment
of post-stroke pathological crying.6
CIT is normally taken as a single daily dose in the morning or
evening with or without food. Food does not increase the
absorption of CIT but helps to prevent nausea. In the therapeutic
dose range, CIT is safe and well tolerated. Recommended doses
range from 20 to 40 mg daily, which results in a plasma concen-
tration range from 30–130 ng mL–1.7 Overdosage may cause
drowsiness, vomiting, dizziness, sweating, nausea, coma, confu-
sion, and heartbeat anomalies.8
Citalopram is absorbed by cytochrome P to its demethylated
metabolites, desmethylcitalopram and didesmethylcitalopram.
Desmethylcitalopram is the chief metabolite and can also
prevent 5-HT reuptake, but is less potent than citalopram.9 Until
recently, citalopram was sold as a racemic mixture, consisting of
50 % R-(–)-citalopram and 50 % S-(+)-citalopram, but as the
S-(+)-enantiomer has the desired antidepressive effect10, it was
recently introduced under the generic name escitalopram.
Various analytical techniques have been developed to deter-
mine citalopram levels in commercial formulations and biologi-
cal samples. These include gas chromatographic, gas chromato-
graphic/mass spectrometric (GC/MS)11,12, high performance
liquid chromatographic (HPLC) with fluorescence13–16, UV16–18,
and MS detectors 19,20, and electrophoretic methods.21–26 Spectro-
fluorimetric27–30 and spectrophotometric31–33 methods have also
been reported for the citalopram determination in pharmaceuti-
cal formulations. Few CL methods have been recently reported
for the determination of citalopram in pharmaceutical prepara-
tions and biological samples.34,35
Chemiluminescence (CL) is a powerful analytical technique
with widespread applications in numerous fields because of its
high sensitivity, rapidity, wide linear range, high signal to noise
ratios (due to the absence of a light source), instrumental
simplicity and affordability, and the comparative absence of
toxic effects.36–41
On the other hand, carbon nanotube (CNT) materials are
attracting considerable research interest. In particular, in addi-
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tion to being small sizes, CNTs have huge surface areas, hollow
or layered structures, high mechanical strengths, and significant
electrical conductivities. These properties are of interest in
various applications, such as, field emission, reinforcing materi-
als for composites, nanoprobes, and chemical sensors.42–46 CNTs
are available as singled-walled carbon nanotubes or multiwall
carbon nanotubes (MWCNTs) according to the number of layers
carbon atom in their walls. Furthermore, when MWCNTs are
treated with a mixture of H2SO4 and HNO3, carboxyl groups are
produced on their walls and some physical properties are
changed. In addition, the presence of oxygen containing func-
tional groups on side walls provides a means of introducing
positively charged species.47–52
In the present study, a CL-based method involving the use
of oxidized multiwall carbon nanotubes (ox-MWCNTs)
grafted with Cu2+ was devised to quantify citalopram levels in
pharmaceutical preparations. We found that ox-MWCNTs/Cu2+
enhanced the CL signal arising from the reaction between
alkaline luminol and H2O2, and that CL intensities were further
boosted by the presence of citalopram. Based on these observa-
tions, we developed a sensitive CL method for the quantification
of citalopram in pharmaceutical preparations. Citalopram was
found to markedly increase the CL intensity of the luminol-
H2O2-ox-MWCNTs/Cu
2+ system and this enhance was propor-
tional to the concentration of citalopram present. After optimiz-
ing experimental parameters, CL intensity was found to be
linear to citalopram concentration in the range 0.2–8.0 µg mL–1
with a detection limit of 2.29 × 10–5 µg mL–1.
2. Experimental
2.1. Materials and Reagents
Reagents used were of high grade purity and double-
deionized water (DI) was used throughout. Luminol (5-amino-2,
3-dihydro-1, 4-phthalazinedione) was purchased from
Sigma-Aldrich (St. Louis, Missouri, US). Hydrogen peroxide and
sodium hydroxide were from the Junsei Chemical Co., Ltd.
Quality Assurance Section 1–6, Ohmano-cho, Koshigaya-shi,
Saitama, 4-0844, Japan. MWCNTs (>93 % purity, 10–40 nm
average diameter, and 1–25 µm long) were brought from CNT
(Daegu, South Korea). Standard reference citalopram was
provided by Z-Jan’s Pharmaceutical Industry (Peshawar, Paki-
stan). Commercial formulations of citalopram, Lopram 20 mg
tablets (manufactured by Hansel Pharmaceuticals (Pvt) Ltd,
Lahore, Pakistan), Citalo 20 mg tablets (manufactured by
Platinum Pharmaceuticals (Pvt) Ltd, Karachi, Pakistan) and
Pramcit 20 mg tablets (manufactured by Nabiqasim Industries
(Pvt) Ltd, Karachi, Pakistan) were purchased locally.
2.2. Preparation of Reagents and Sample Solutions
Luminol stock solution (4 × 10–3 M) was prepared by dissolving
0.035 g of luminol in 4.5 mL of 0.1 M NaOH, diluted to 50 mL with
deionized (DI) water, and stored at 4 °C. Hydrogen peroxide
solution (4 M) was prepared by diluting 10.213 mL of 30 % H2O2
to 25 mL with DI water. Sodium hydroxide (0.1 M) solution was
prepared by dissolving 2.0 g of NaOH in 50 mL DI water.
Working solutions were prepared freshly before use from stock
solutions by proper dilution with DI water. A standard stock
solution of citalopram (250 µg mL–1) was prepared by dissolving
0.0125 g of citalopram standard in 2 mL of distilled ethanol, and
diluting to 50 mL with DI water. Working solutions of 10 µg mL–1
and 5 µg mL–1 citalopram were prepared daily by diluting proper
amounts of the stock solution with DI water.
2.3. Synthesis of Oxidized MWCNTs
Ox-MWCNTs were prepared as previously described by Rosca
et al.53,54 Briefly, 0.5 g pristine MWCNTs (p-MWCNTs) were
added to 200 mL nitric acid solution in a round-bottomed glass
flask. p-MWCNTs were dispersed by sonication for 1 h using an
ultrasonic bath (JAC Ultra-sonic 4020p, KODO, South Korea),
and the mixture was then refluxed at 120 °C for 12 h under nitro-
gen. After cooling, the MWCNTs were washed and filtered
several times using DI water and a 0.22 µm membrane nitrocellu-
lose filter (Millipore, USA). The MWCNTs so obtained were then
dried in an oven at 60 °C for 48 h  (Fig. 1).
2.4. Synthesis of Cu2+-grafted Oxidized Multiwall
Carbon Nanotubes
Oxidized MWCNTs (0.1 g) were added to 20 mL of a 1 × 10–3 M
Cu (II) solution and dispersed by sonication for 30 min. After
cooling, the ox-MWCNTs/Cu2+ were washed and filtered
through a nitrocellulose filter (0.20 µm; Millipore, USA). The
obtained ox-MWCNTs/Cu2+ were then dried at 60 °C for 24 h
(Fig. 1).
2.5. Instrument
A Hitachi F-4500 spectrofluorometer was used to detect and
record CL produced by the luminol-H2O2-ox-MWCNTs/Cu
2+
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Figure 1 Schematic diagram of the preparation of oxidized MWCNTs and Cu2+-grafted MWCNTs.
system. For CL measurements, the light source of the spectro-
fluorometer was switched off and only the photomultiplier tube
(Model, R 928, Hamamatsu, Japan) was used. The slit width
of the emission monochromators was 5 nm and the power
supply of the photomultiplier tube used to detect CL signals was
700 V. Light-producing reactions were carried out in a standard
1 × 1 cm quartz cell placed in the spectrofluorometer cell holder.
2.6. Analytical Procedure
Analytical procedure consisted of adding the following quan-
tities of equilibrated solutions to the CL reaction cell using a
micropipette. Citalopram stock solution to give final concentra-
tion of 0.2–8.0 µg mL–1, 4 × 10–4 g ox-MWCNTs/Cu2+, 400 µL of
NaOH solution (8 × 10–3 mol L–1), and 400 µL luminol (4 × 10–3
mol L–1). The kinetic-curve of the CL signal was measured at
430 nm after injecting of 400 µL (4 × 10–2 mol L–1) of H2O2 into cells
to initiate the CL reaction. CL intensities (DI) were calculated
using DI = Is– Io, where Isand Io are CL signals in the presence and
absence of citalopram, respectively.
2.7. Application to Pharmaceutical Preparations
Five tablets each containing 20 mg of active citalopram were
weighed and weights were averaged. The tablets were then
powdered in a mortar. The powder equivalent of 0.0125 g
citalopram was dissolved in 2 mL of ethanol, approximately
10 mL of DI water was added, and mixture sonicated for 10 min.
The resultant solution was then filtered and diluted to 50 mL
with DI water. An appropriate volume of this solution was then
diluted with DI water to provide a citalopram concentration in
the working range. A certain volume of this solution was then
analyzed using the above described procedure and amount of
citalopram present per tablet was calculated by the calibration
equation.
3. Results and Discussion
3.1. Characterization of MWCNTs, Oxidized MWCNTs and
Cu2+/ox-MWCNTs
The morphologies of pristine-MWCNTs, ox-MWCNTs, and
ox-MWCNTs/Cu2+ were examined by scanning electron micros-
copy (SEM) (S-4200, HITACHI, Japan). The Pristine-MWCNTs
appeared as separate thread-like carbon fibres (Fig. 2(a)),
whereas ox-MWCNTs were aggregated (Fig. 2(b)), and Cu2+
coated ox-MWCNTs were more aggregated (Fig. 2(c)).
3.2. CL Characterization
A CL emission spectrum of the luminol-H2O2-citalopram-
MWCNTs/Cu2+ system is presented in Fig. 3. As shown in
Fig. 3(a), the luminol-H2O2 system produced a weak CL signal,
which was not enhanced by the addition of ox-MWCNTs
(Fig. 3(b)). However, the addition of ox-MWCNTs/Cu2+ to the
luminol-H2O2 system augmented the CL signal (Fig 3(c)), and
the addition of citalopram markedly enhanced the signals
obtained (Fig 3(d)), which exhibited maximum intensity at
430 nm. Furthermore, the CL intensity of the luminol-H2O2-
citalopram-MWCNTs/Cu2+ system was proportional to the
concentration of citalopram present.
3.3. Optimization of the Reagents Concentration
The effect of the amount of MWCNTs/Cu2+ used was investi-
gated in the range 2–10 × 10–4 g. Maximum CL intensity of the
luminol-H2O2-citalopram-MWCNTs/Cu
2+ system was achieved
at 4 × 10–4 g (Fig. 4), and thus, this amount was used in further
experiments. The effect of sodium hydroxide concentration on
the luminol-H2O2-citalopram-MWCNTs/Cu
2+ system was inves-
tigated in the range 2–12 × 10–3 mol L–1. CL intensity was found
to peak at a NaOH concentration of 8 × 10–3 mol L–1 (Fig. 5). The
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Figure 2 SEM images of (a) Pristine MWCNTs; (b) Oxidized MWCNTs; (c) Oxidized MWCNTs/Cu2+.
effect of luminol concentration on CL intensity was also studied
in the range 1–6 × 10–3 mol L–1. CL intensity peaked at a luminol
concentration of 4 × 10–3 mol L–1 (Fig. 6). The effects of H2O2
concentration were examined in the range 1–6 × 10–2 mol L–1. CL
intensity increased with H2O2 concentration to 4 × 10
–2 mol L–1
and then plateaued (Fig 7).
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Conditions: citalopram, 8.0 µg mL–1; Cu2+/MWCNTs, 4 × 10–4 g; NaOH, 8 × 10–3 mol L–1; luminol, 4 × 10–3 mol L–1; H2O2, 4 × 10
–2 mol L–1
Figure 4 Effect of Cu2+/MWCNTs dosage on CL intensity.
Conditions: citalopram, 8.0 µg mL–1; Cu2+/MWCNTs, 2–10 × 10–4 g; NaOH, 6 × 10–3 mol L–1; luminol, 2 × 10–3 mol L–1; H2O2, 3 × 10
–2mol L–1; leme 430 nm.
Figure 5 Effect of NaOH concentration on CL intensity.
Conditions: citalopram, 8.0 µg mL–1; Cu2+/MWCNTs , 4 × 10–4 g; NaOH, 2–12 × 10–3 mol L–1; luminol, 2 × 10–3 mol L–1; H2O2, 3 × 10
–2 mol L–1; leme
430 nm.
3.4. Analytical Features of Merit
Under optimum experimental conditions, the concentration of
citalopram and chemiluminescence intensity exhibited a linear
relationship in the range 0.2–8.0 µg mL–1 with a correlation coef-
ficient of 0.996–0.9977 (Fig. 8a,b). Limit of detection (LOD) was
defined as the concentration of citalopram that produced a CL
intensity three times the blank standard deviation (LOD = 3
Sb/m), whereas limit of quantification (LOQ) was defined as the
concentration of the citalopram that produced a CL intensity ten
times the blank standard deviation (LOQ = 10 Sb/m). Calculated
LOD and LOQ values were 2.29 × 10–5 µg mL–1 and 7.64 ×
10–5 µg mL–1 respectively. The linear regression equation, its
slope, intercept, and correlation coefficient, and the relative
standard deviation of the response factor are provided in
Table 1. The sensitivity of the developed method is compared
with other described citalopram methods in Table 2. The table
shows that the sensitivity of the devised method is greater than
that of any of the previously described methods.
3.5. Interference Effects
Interference by common excipients like glucose, starch, fruc-
tose, lactose, magnesium stearate, and talc were studied. The
interference study was conducted by preparing samples
containing fixed amounts of citalopram (0.2 µg mL–1) and differ-
ent concentrations (5, 10, 20, and 40-fold concentrations) of
excipients. No interferences were observed by these common
excipients (Fig. 9).
3.6. Reliability of the Method
The precision of the proposed method was studied by analyz-
ing pure citalopram and pharmaceutical formulations using
three different concentrations of each in triplicate. Results are
given in Table 3 for pure citalopram and in Table 4 for pharma-
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Figure 6 Effect of luminol concentration on CL intensity.
Conditions: citalopram, 8.0 µg mL–1; Cu2+/MWCNTs, 4 × 10–4 g; NaOH, 8 × 10–3 mol L–1; luminol, 1–6 × 10–3 mol L–1; H2O2, 3 × 10
–2 mol L–1; leme 430 nm.
Figure 7 Effect of H2O2 concentration on CL intensity.
Conditions: citalopram, 8.0 µg mL–1; Cu2+/MWCNTs, 4 × 10–4 g; NaOH, 8 × 10–3 mol L–1; luminol, 4 × 10–3 mol L–1; H2O2, 1–6 × 10
–2 mol L–1; leme 430 nm.




Linear range /µg mL–1 0.2–8.0
Limit of detection /µg mL–1 2.29 × 10–5
Limit of quantification /µg mL–1 7.64 × 10–5
Regression equation (y) Y = 658.5X – 23.7
Slope (b) 658.5
Intercept (a) 23.7
Correlation coefficient /r 0.9977
Standard deviation /µg mL–1 5.02 × 10–3
Relative standard deviation /% 2.59
ceutical formulations. Percent recoveries were calculated and
obtained in the range of 98.67–101.46 % for the pure form and
97.06–101.50 % for commercial formulations with low relative
standard deviation value. The accuracy of the method was
studied by the standard addition method using three different
tablet brands Citalo, Lopram, and Pramcit (each containing
20 mg of citalopram). Definite amounts (0.1973, 0.4059, and
0.6081 µg mL–1) of pure citalopram solution were added to tablet
solutions (0.20 µg mL–1) and analyzed using the described proce-
dure.
Recoveries were calculated and obtained in the range of
97.38–101.72 % (Table 5), demonstrating the excellent accuracy of
the developed method for the determination of citalopram in
commercial formulations.
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Figure 8 a, Linear range of citalopram. b, Calibration curve of citalopram.
Conditions for (a): citalopram, 0.2–8.0 µg mL–1; Cu2+/MWCNTs, 4 × 10–4 g; NaOH, 8 × 10–3 mol L–1; luminol, 4 × 10–3 mol L–1; H2O2, 4 × 10
–2 mol L–1;
leme 430 nm.
Conditions for (b): citalopram, 0.2–1.0 µg mL–1; Cu2+/MWCNTs, 4 × 10–4 g; NaOH, 8 × 10–3 mol L–1; luminol, 4 × 10–3 mol L–1; H2O2, 4 × 10
–2 mol L–1;
leme 430 nm.
Table 2 Comparison of the present method with other reported methods for the determination of citalopram.
Methods Linear range Limit of detection (LOD) References
HPLC 20–80 µg L–1 5 µg L–1 [21]
Capillary zone electrophoretic 1–20 mg L–1 0.03 mg L–1 [24]
Spectrofluorimetry 5.0 × 10–7– 2.5 × 10–6 M 8.0 × 10–6M [29]
Spectrophotometry 10–250 µg mL–1 5.2 µg mL–1 [30]
Spectrophotometry 8–240 µg mL–1 4.14 µg mL–1 [31]
Chemiluminescence 0.2–8.0 µg mL–1 2.29 × 10–5µg mL–1 Present method
Table 3 Accuracy and precision of the devised method for the quantifica-
tion of pure citalopram.
Amount taken Amount found % Recovery ± RSD
/µg mL–1 /µg mL–1
0.20 0.197 98.67 ± 0.93 %
0.40 0.406 101.46 ± 2.46 %









The proposed method was fruitfully applied to the determina-
tion of citalopram in three different pharmaceutical prepara-
tions. The results obtained agreed well with manufacturers’
claims (Table 6), indicating that the method can be used to quan-
tify citalopram levels in commercial formulations.
4. Conclusion
A simple precise accurate and sensitive method was devel-
oped for the quantification of citalopram. The method is based
on the enhancement of citalopram CL of the luminol-H2O2-
MWCNTs/Cu2+ system. The method has a wider linear range
and lower limits of detection and quantification than other
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Table 4 Evaluation of the accuracy and precision of the devised method for citalopram quantification in pharmaceutical preparations.
Pharmaceutical Amount taken Amount found % Recovery ± RSD
preparations /µg mL–1 /µg mL–1
Citalo, 20 mg tablet 0.20 0.1987 99.38 ± 2.29 %
0.40 0.3977 99.44 ± 2.35 %
0.60 0.6085 101.42 ± 3.03 %
Lopram, 20 mg tablet 0.20 0.1941 97.06 ± 3.27 %
0.40 0.3978 99.45 ± 1.26 %
0.60 0.5944 99.07 ± 1.64 %
Pramcit, 20 mg tablet 0.20 0.1965 98.29 ± 3.74 %
0.40 0.4060 101.50 ± 2.67 %
0.60 0.5945 99.08 ± 1.83 %
Each result is the averages of separate triplicate analyses; RSD = Relative standard deviation.
Table 5 Recovery percentages for citalopram in commercial tablet formulations determined by the standard addition method.
Pharmaceutical Amount added Amount found % Recovery ± RSD
preparation /µg mL–1 /µg mL–1
Citalo, 20 mg tablet 0.1973 0.1979 100.31 ± 4.52 %
0.4058 0.4081 100.57 ± 2.42 %
0.6081 0.6038 99.30 ± 1.28 %
Lopram, 20 mg tablet 0.1973 0.2007 101.72 ± 2.77 %
0.4058 0.4076 100.45 ± 3.64 %
0.6081 0.5946 97.77 ± 1.78 %
Pramcit, 20 mg tablet 0.1973 0.1992 100.97 ± 3.80 %
0.4058 0.3952 97.38 ± 3.67 %
0.6081 0.5972 98.20 ± 2.87 %
Each result is the averages of separate triplicate analyses; RSD = Relative standard deviation.
Figure 9 Effect of excipients on CL intensity.
described methods. In addition, it was successfully applied for
the determination of citalopram in pharmaceutical preparations
with good recovery and excellent reproducibility. The com-
monly present excipients in commercial formulations did not
interfere with the analysis. Accordingly, we conclude that the
developed method is appropriate for the quantification of
citalopram in quality control laboratories and industrial fields.
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